ResMed (NYSE: RMD) reported Q3 EPS of $2.13, $0.20 better than the analyst estimate of $1.93. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.